Techdow
Biosimilar developer, China. 1 development product across 1 molecule: enoxaparin sodium.
First approval in the Atlas: Sep 2016, Inhixa, enoxaparin sodium (EMA)
FDAproducts approved0
EMAproducts approved1
PMDAproducts approved0
HCproducts approved1
CDSCOproducts approved0
EDEproducts registered1
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Enoxaparin sodium | Inhixa | · | Sep 2016 | · | Dec 2020 | · | Jun 2019 |
Month shown is the first approval or registration of that product in that market.
Chronology
- EMASep 2016Inhixa, enoxaparin sodium
- EDEJun 2019Inhixa, enoxaparin sodium
- HCDec 2020Redesca, enoxaparin sodium
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.